Get the Stockscreener App
1.80
2.22%
0.00
Curis Inc stock is traded at $1.80, with a volume of 320.56K.
It is up +2.22% in the last 24 hours and down -60.26% over the past month.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
See More
Previous Close:
$1.80
Open:
$2.03
24h Volume:
320.56K
Relative Volume:
0.13
Market Cap:
$4.37M
Revenue:
$7.06M
Net Income/Loss:
$-21.17M
P/E Ratio:
-0.0754
EPS:
-23.879
Net Cash Flow:
$-28.95M
1W Performance:
-49.73%
1M Performance:
-60.26%
6M Performance:
+73.58%
1Y Performance:
+0.55%
1-Day Range:
$1.80
$2.03
1-Week Range:
$1.54
$3.37
52-Week Range:
$0.1806
$6.74
Curis Inc Stock (CRIS) Company Profile
Name
Curis Inc
Sector
Industry
Phone
617-503-6500
Address
128 SPRING STREET, LEXINGTON, MA
Compare CRIS vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRIS
Curis Inc
|
1.80 | 4.37M | 7.06M | -21.17M | -28.95M | -23.88 |
VRTX
Vertex Pharmaceuticals Inc
|
515.63 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
807.01 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
991.71 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
213.05 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.46 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Nov-17-23 | Initiated | Truist | Buy |
| Apr-04-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-13-21 | Initiated | Raymond James | Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Jul-29-20 | Initiated | Laidlaw | Buy |
| Jul-17-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Mar-02-16 | Initiated | Sun Trust Rbsn Humphrey | Buy |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Aug-11-15 | Initiated | FBR Capital | Outperform |
| Jan-22-15 | Reiterated | Oppenheimer | Outperform |
| Jan-21-15 | Reiterated | ROTH Capital | Buy |
| May-09-14 | Reiterated | Oppenheimer | Outperform |
| Oct-02-13 | Initiated | Robert W. Baird | Outperform |
| Sep-30-13 | Initiated | Chardan Capital Markets | Buy |
| Nov-14-12 | Initiated | Stifel Nicolaus | Hold |
| Jan-31-12 | Reiterated | Brean Murray | Buy |
| Jan-31-12 | Reiterated | Summer Street Research | Buy |
| Dec-09-11 | Initiated | Oppenheimer | Outperform |
| Oct-06-11 | Initiated | Summer Street Research | Buy |
| Sep-22-11 | Initiated | MLV Capital | Buy |
| Mar-21-11 | Reiterated | Brean Murray | Buy |
| Feb-26-10 | Reiterated | Roth Capital | Buy |
| Jan-07-10 | Initiated | Roth Capital | Buy |
View All
Curis Inc Stock (CRIS) Latest News
CRIS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $43 - GuruFocus
Curis announces pricing of $5.6M public offering - TipRanks
Curis Inc.’s 1-for-20 Reverse Split Raises Liquidity Concerns and Odd-Lot Trading Risks - TipRanks
Curis Stock Price Forecast. Should You Buy CRIS? - StockInvest.us
Curis Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Curis: Q2 Earnings Snapshot - Caledonian Record
CURIS INC 10-Q Summary: Revenue $0 Net income ($8.58M), EPS ($4.02) — 10-Q Summary - TradingView
Curis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Curis Prices $5.6 Million Public Offering With Healthcare-Focused Institutional Investors - marketscreener.com
CRIS Looks 91.8% Undervalued on GF Value™ Amid Unprofitability C - GuruFocus
Curis prices $5.6 million public offering at $1.50 per share - Investing.com
Curis prices $5.6 million public offering at $1.50 per share By Investing.com - Investing.com UK
Curis, Inc. Announces Pricing of $5.6 Million Public Offering - PR Newswire
CURIS INC SEC Filing (Aug 13, 2026) - Stock Titan
IPO Databook: Curis (CRIS US)Aug 2026 - smartkarma.com
Curis (CRIS) seeks cash via best-efforts stock and warrant offering amid going-concern risk - Stock Titan
Curis Inc (CRIS) Stock News Today - TradingKey
Curis Inc expected to post a loss of $7.84 a shareEarnings Preview - TradingView
Curis, Inc. (CRIS) stock price, news, quote and history - au.finance.yahoo.com
Curis Inc (CRIS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Curis (CRIS) Stock Fair Value Moves Lower After Emavusertib TakeAim Model Rework - finance.yahoo.com
Primer: Curis Inc (CRIS US)Aug 2026 - Smartkarma
Curis Inc expected to post a loss of $7.47 a shareEarnings Preview - TradingView
Curis Regains Nasdaq Compliance, Faces One-Year Monitoring - TipRanks
Curis doses first five patients in leukemia drug study - Investing.com
JonesTrading Maintains Curis(CRIS.US) With Buy Rating, Cuts Target Price to $20 - moomoo.com
CRIS Q2'26 Earnings: EPS estimate is (6.96) USD - TradingView
Curis Inc (CRIS) Institutional Confidence - TradingKey
Curis Inc (CRIS) Cash Flow - TradingKey
Curis Inc (CRIS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus - Yahoo Finance
CRIS|Curis Inc|Price:5.190|Chg%:+0.300 - TradingKey
TradingKey - TradingKey
Curis Inc (CRIS) Income Statement - TradingKey
Curis Inc (CRIS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Curis Inc (CRIS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Curis Inc (CRIS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CRIS Maintained by HC Wainwright & Co. -- Price Target Raised to $43.00 - GuruFocus
Curis, Inc. Revenue Breakdown – NASDAQ:CRIS - TradingView
CRIS Q1 2026 Earnings: Significant Earnings Miss Amid Broader ConcernsRevenue Per Share - dars.gov.et
CRIS Q2'26 Earnings: revenue estimate is 1.00M USD - TradingView
Curis stock jumps 11% on positive emavusertib trial data - Investing.com
Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates - Benzinga
Curis (CRIS) Stock Sees Fair Value Lift As Analysts Back Leadership And Consumer Focus - Yahoo Finance
Curis Q2 2026: Updated Clinical Data for Emavusertib Trials - grafa.com
Curis stock jumps 11% on positive emavusertib trial data By Investing.com - Investing.com South Africa
Curis Inc Positive Emavusertib Update Transcript - GuruFocus
Curis shares surge after updated emavusertib data strengthens clinical outlook (NASDAQ:CRIS) - Yahoo Finance
Curis reports updated trial data for emavusertib in lymphoma By Investing.com - Investing.com Nigeria
Curis reports updated trial data for emavusertib in lymphoma - Investing.com
Curis Announces Positive Emavusertib Update - PR Newswire
Curis Inc Stock (CRIS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):